HGH and Thymus Regeneration: The Fahy TRIIM Trial Protocol

The thymus is one of the most striking examples of programmed organ involution in the human body. From a peak weight of ~30 g in adolescence, the thymus shrinks and becomes increasingly replaced by fat tissue, losing the vast majority of its T-cell-producing function by age 60. This involution is one of the central drivers of immunosenescence - the age-related decline in immune competence that underlies infection vulnerability, cancer susceptibility, and reduced vaccine response in older adults.

For decades the prevailing assumption was that thymic involution was permanent and unreversible. Then, in 2019, Gregory Fahy and colleagues published the results of the TRIIM (Thymus Regeneration, Immunorestoration, and Insulin Mitigation) trial in Aging Cell - and demonstrated, in humans, that the thymus could be regrown using a specific combination of recombinant human growth hormone (rhGH), DHEA, and metformin.

This article reviews the TRIIM protocol as published, the mechanistic case for HGH-driven thymic regrowth, and the follow-up TRIIM-X trial currently underway.

Research framing. This article is an educational review of a published clinical trial and the surrounding research on HGH and thymic biology. It is not medical advice. Research compounds discussed are sold strictly for laboratory study and are not approved for human consumption. See our research-use-only disclaimer.

The TRIIM Trial: Design and Protocol

TRIIM was a year-long, open-label, single-arm intervention study published by Fahy et al. in Aging Cell (2019). Nine generally healthy men aged 51 to 65 received the following daily regimen:

For an 80 kg (~176 lb) man, the mean HGH dose works out to roughly 1.0-1.2 mg/day, equivalent to ~3-3.5 IU/day of HGH (using the conventional conversion of 1 mg rhGH ≈ 3 IU).

Why the three-drug combination?

HGH alone has a well-known issue: it produces insulin resistance. Fahy's design used DHEA and metformin specifically as insulin-sensitizing counter-agents to neutralize this side effect while preserving HGH's thymic and immune effects.

• HGH drives thymic epithelial cell regeneration via direct GH receptor activation and IGF-1 mediated effects.
• DHEA counters HGH-induced glucose intolerance and provides upstream substrate for sex-steroid synthesis that declines with age.
• Metformin improves insulin sensitivity, activates AMPK, and is independently associated with reduced all-cause mortality and reduced cancer incidence in observational data.

The combination is sometimes called the "Fahy stack" or "TRIIM stack" in longevity research circles.

The Results: Thymic Regrowth and Epigenetic Age Reversal

The TRIIM paper reported several striking findings after one year:

Thymic regrowth on MRI

In 7 of 9 participants, MRI imaging showed:

• Replacement of accumulated thymic fat with functional thymic tissue
• Restored thymic density on a quantitative imaging measure

Two participants had already lost essentially all thymic function at baseline and showed minimal anatomical regrowth, suggesting a threshold below which regrowth becomes harder.

Restored T-cell production

Blood markers consistent with renewed thymic output:

• Increased CD4+/CD8+ T-cell ratios
• Reduced PD-1+ exhausted T-cells
• Reduced monocyte counts (consistent with reduced compensatory innate immunity)
• Increased TREC (T-cell receptor excision circles), a direct biomarker of recent thymic output

Epigenetic age reversal

This was the headline result. Using four established epigenetic clocks (Horvath, Hannum, GrimAge, and PhenoAge), participants showed:

• An average epigenetic age reversal of 1.5 years over the 12-month intervention
• The reversal accelerated over time and persisted for at least 6 months after the trial ended

This is the first peer-reviewed human study to demonstrate biological age reversal on multiple established epigenetic clocks simultaneously.

Safety

All nine participants completed the trial. Insulin sensitivity was preserved by the DHEA + metformin combination. No serious adverse events were reported.

The Mechanism: How HGH Regrows the Thymus

The thymus contains specialized thymic epithelial cells (TECs) that "educate" developing T cells. Two facts make HGH a plausible thymus-regeneration agent:

1. TECs express GH receptors and IGF-1 receptors at high density. GH/IGF-1 signaling is one of the dominant trophic inputs to thymic epithelium.
2. Thymic involution correlates with declining GH/IGF-1 axis activity. Adult GH-deficient patients show accelerated thymic atrophy that is partially reversible with GH replacement, predating the TRIIM trial by decades in case reports.

Mechanistically, HGH appears to:

• Stimulate TEC proliferation directly via GH receptor
• Increase IGF-1, which promotes both TEC and thymocyte survival
• Reduce thymic adiposity by suppressing the adipogenic differentiation pathway that progressively replaces TECs with fat
• Restore the chemokine signaling that recruits T-cell progenitors from the bone marrow

The combined effect is anatomical regrowth of thymic tissue and resumption of T-cell output.

TRIIM-X: The Follow-Up Trial

Following the 2019 publication, Fahy's team launched TRIIM-X, a larger follow-up trial of approximately 85 participants designed to:

• Replicate the thymic regrowth and epigenetic age reversal findings
• Test the protocol in women (TRIIM enrolled only men, since estrogen's interactions with thymic biology added complexity)
• Test in older participants (the original trial capped at 65)
• Refine dose-response curves

Results from TRIIM-X have been progressively released and broadly support the TRIIM findings, though some refinements to the dosing have been suggested (lower HGH starting doses, more individualized IGF-1 targeting).

How Researchers Have Adapted the Protocol

In the years since TRIIM was published, the protocol has been adapted in research-community discussions in several ways:

Conservative/longevity-aligned dose

Closer-to-TRIIM dose

The conservative dose is more commonly discussed in the broader longevity-research community; the closer-to-TRIIM dose reflects what was actually tested in the published trial.

Cycling vs. continuous

TRIIM ran continuous daily dosing for 12 months. Some researchers have explored cycling on/off (e.g., 5 days on, 2 days off; or 12 weeks on, 4 weeks off) on the rationale that pulsed HGH exposure may better mimic physiological pulsatile release and reduce IGF-1 receptor downregulation. This is hypothesis rather than tested protocol.

FAQ

What is the Fahy TRIIM trial?

TRIIM (Thymus Regeneration, Immunorestoration, and Insulin Mitigation) is a 2019 human clinical trial published in Aging Cell by Gregory Fahy and colleagues. Nine men aged 51-65 took recombinant human growth hormone (rhGH) combined with DHEA and metformin for one year. The trial demonstrated thymic regrowth on MRI in 7 of 9 participants and an average epigenetic age reversal of 1.5 years across four independent epigenetic clocks - the first peer-reviewed human demonstration of biological age reversal.

Can HGH actually regrow the thymus in adults?

Yes - the TRIIM trial provided direct MRI evidence of thymic regeneration in adult humans following 12 months of rhGH + DHEA + metformin. Thymic epithelial cells express growth hormone and IGF-1 receptors at high density, and GH/IGF-1 axis signaling is one of the dominant trophic inputs to the thymus. The effect was strongest in participants who still had some preserved thymic function at baseline.

What HGH dose was used in the TRIIM trial?

Participants started at 0.015 mg/kg/day of recombinant human growth hormone, titrated by IGF-1 response to keep IGF-1 near 225 ng/mL. The mean dose ended up at approximately 0.013 mg/kg/day, which works out to about 1.0-1.2 mg/day (~3-3.5 IU/day) for an 80 kg adult.

Why was DHEA and metformin combined with HGH?

HGH causes insulin resistance as a known side effect. DHEA and metformin were added specifically as insulin-sensitizing counter-agents to neutralize this side effect while preserving HGH's thymic and immune effects. The DHEA dose was 50 mg/day (some participants 25 mg) and metformin was 500-1000 mg/day. DHEA also provides upstream substrate for declining sex-steroid synthesis with age.

What were the epigenetic age reversal results?

After 12 months on the TRIIM protocol, participants showed an average epigenetic age reversal of 1.5 years across four independent epigenetic clocks (Horvath, Hannum, GrimAge, and PhenoAge). The reversal accelerated over the course of the year and persisted for at least 6 months after the intervention ended. This was the first peer-reviewed human study to show biological age reversal on multiple clocks simultaneously.

What is the TRIIM-X follow-up trial?

TRIIM-X is the larger follow-up trial of approximately 85 participants designed to replicate TRIIM's findings, extend the protocol to women and older participants, and refine dose-response curves. Results released so far have broadly supported the TRIIM findings, with some suggestions for lower starting HGH doses and more individualized IGF-1 targeting.

Is HGH-based thymic regeneration safe?

All nine participants in the original TRIIM trial completed the 12-month protocol without serious adverse events. Insulin sensitivity was preserved by the DHEA + metformin combination. The longer-term and larger TRIIM-X dataset will further characterize the safety profile. HGH research generally requires monitoring for IGF-1 elevation, blood-sugar effects, and joint/edema-related side effects.

Closing Note

The TRIIM trial represents one of the more striking results in published longevity research: a multi-decade-old assumption (that the human thymus cannot be regrown in adulthood) was overturned by a small, well-designed clinical trial using a three-drug combination that addresses HGH's main metabolic side effect head-on. The protocol is conceptually simple, the doses are modest, and the biomarker results have so far held up in larger follow-up.

For researchers working in this space, the original TRIIM paper (Fahy et al., Aging Cell 2019) remains essential reading. The HGH research-grade reference standard is available in our catalog.

Research compounds discussed in this article are sold strictly for laboratory study and are not approved for human consumption.